Aurobindo Splits Out Biosimilars Business

Firm Upbeat On Outlook As It Seeks FDA Desk Reviews For Three Units

After double-digit growth in formulations sales across geographies in the fourth quarter, Aurobindo expects to continue the momentum this fiscal year. Meanwhile, it might look for partners for its biologics business, which it has now transferred to its fully-owned subsidiary for $48m.

Business growth
Aurobindo Looks For Growth As It Carves Out Biologics Business • Source: Shutterstock

Aurobindo Pharma doesn’t see major disruptions to its business on account of COVID-19 and expects its strong showing in the fourth quarter of fiscal 2020 to continue in the current fiscal year as well. A growth in volumes, backed by 50-60 product launches, should see gross margins of 58-59%.

Higher sales of antibiotics, antivirals and protein drugs due to short-term shortages and anticipatory stocking by customers as the pandemic...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Strategy

More from Business